AU2001234978A1 - Therapeutic platelets and methods - Google Patents

Therapeutic platelets and methods

Info

Publication number: AU2001234978A1
Authority: AU; Australia
Prior art keywords: platelets; trehalose; freeze; dried; composition
Prior art date: 2000-02-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001234978A

Other languages

English (en)

Inventor

John H. Crowe

Ann E Oliver

Fern Tablin

Naomi J. Walker

Willem F. Wolkers

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California San Diego UCSD

Original Assignee

University of California

University of California Berkeley

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-10

Filing date

2001-02-08

Publication date

2001-08-20

2001-02-08 Application filed by University of California, University of California Berkeley filed Critical University of California

2001-08-20 Publication of AU2001234978A1 publication Critical patent/AU2001234978A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 29
230000001225 therapeutic effect Effects 0.000 title claims description 14
210000001772 blood platelet Anatomy 0.000 claims description 310
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 110
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 110
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 110
239000000203 mixture Substances 0.000 claims description 37
239000000872 buffer Substances 0.000 claims description 35
210000004027 cell Anatomy 0.000 claims description 35
238000011068 loading method Methods 0.000 claims description 34
238000001035 drying Methods 0.000 claims description 31
238000011534 incubation Methods 0.000 claims description 31
108090000190 Thrombin Proteins 0.000 claims description 28
229960004072 thrombin Drugs 0.000 claims description 27
239000003814 drug Substances 0.000 claims description 22
230000004044 response Effects 0.000 claims description 21
239000000556 agonist Substances 0.000 claims description 18
238000004108 freeze drying Methods 0.000 claims description 18
230000008569 process Effects 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
230000023597 hemostasis Effects 0.000 claims description 15
241000282414 Homo sapiens Species 0.000 claims description 14
238000007710 freezing Methods 0.000 claims description 14
230000008014 freezing Effects 0.000 claims description 14
230000004071 biological effect Effects 0.000 claims description 12
229940124597 therapeutic agent Drugs 0.000 claims description 11
238000002560 therapeutic procedure Methods 0.000 claims description 11
230000035602 clotting Effects 0.000 claims description 9
241000894007 species Species 0.000 claims description 8
239000003242 anti bacterial agent Substances 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
229920001542 oligosaccharide Polymers 0.000 claims description 7
150000002482 oligosaccharides Chemical class 0.000 claims description 7
238000001816 cooling Methods 0.000 claims description 6
239000011159 matrix material Substances 0.000 claims description 6
229920006395 saturated elastomer Polymers 0.000 claims description 6
102000008186 Collagen Human genes 0.000 claims description 5
108010035532 Collagen Proteins 0.000 claims description 5
229920001436 collagen Polymers 0.000 claims description 5
230000008884 pinocytosis Effects 0.000 claims description 5
229940121375 antifungal agent Drugs 0.000 claims description 4
230000003115 biocidal effect Effects 0.000 claims description 4
238000009826 distribution Methods 0.000 claims description 4
239000003102 growth factor Substances 0.000 claims description 4
108010081391 Ristocetin Proteins 0.000 claims description 3
239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
230000000843 anti-fungal effect Effects 0.000 claims description 3
239000003080 antimitotic agent Substances 0.000 claims description 3
BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 claims description 3
230000001404 mediated effect Effects 0.000 claims description 3
229950004257 ristocetin Drugs 0.000 claims description 3
101000621371 Homo sapiens WD and tetratricopeptide repeats protein 1 Proteins 0.000 claims 1
101000892274 Human adenovirus C serotype 2 Adenovirus death protein Proteins 0.000 claims 1
241000124008 Mammalia Species 0.000 claims 1
101000820656 Rattus norvegicus Seminal vesicle secretory protein 4 Proteins 0.000 claims 1
230000001407 anti-thrombic effect Effects 0.000 claims 1
229960005188 collagen Drugs 0.000 claims 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
238000011084 recovery Methods 0.000 description 18
239000000243 solution Substances 0.000 description 15
RPKCZJYDUKVMGF-UHFFFAOYSA-L lucifer yellow carbohydrazide dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(NC(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N RPKCZJYDUKVMGF-UHFFFAOYSA-L 0.000 description 13
230000007704 transition Effects 0.000 description 13
229940079593 drug Drugs 0.000 description 11
239000000725 suspension Substances 0.000 description 11
208000027418 Wounds and injury Diseases 0.000 description 10
238000012377 drug delivery Methods 0.000 description 10
230000002776 aggregation Effects 0.000 description 9
238000004220 aggregation Methods 0.000 description 9
239000000306 component Substances 0.000 description 9
239000000463 material Substances 0.000 description 9
206010052428 Wound Diseases 0.000 description 8
238000004321 preservation Methods 0.000 description 8
239000012160 loading buffer Substances 0.000 description 7
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
229960000711 alprostadil Drugs 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
239000012528 membrane Substances 0.000 description 6
230000000284 resting effect Effects 0.000 description 6
102000009027 Albumins Human genes 0.000 description 5
108010088751 Albumins Proteins 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
239000002577 cryoprotective agent Substances 0.000 description 5
230000010118 platelet activation Effects 0.000 description 5
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 5
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
229920002307 Dextran Polymers 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
229930040373 Paraformaldehyde Natural products 0.000 description 4
239000012503 blood component Substances 0.000 description 4
229920002866 paraformaldehyde Polymers 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
206010053567 Coagulopathies Diseases 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000003550 marker Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004660 morphological change Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
210000004623 platelet-rich plasma Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
238000005406 washing Methods 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
-1 antifungals Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000004067 bulking agent Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000000834 fixative Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000000859 sublimation Methods 0.000 description 2
230000008022 sublimation Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
239000003634 thrombocyte concentrate Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000632511 Daviesia arborea Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
241000282324 Felis Species 0.000 description 1
229920001612 Hydroxyethyl starch Polymers 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108010035766 P-Selectin Proteins 0.000 description 1
102100023472 P-selectin Human genes 0.000 description 1
125000002626 PGE1 group Chemical group 0.000 description 1
102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000002729 catgut Substances 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000005138 cryopreservation Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000001159 endocytotic effect Effects 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
229920006262 high density polyethylene film Polymers 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
239000000819 hypertonic solution Substances 0.000 description 1
229940021223 hypertonic solution Drugs 0.000 description 1
HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
229960002240 iloprost Drugs 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
230000002885 thrombogenetic effect Effects 0.000 description 1
238000002834 transmittance Methods 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
238000012800 visualization Methods 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/128—Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Environmental Sciences (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Dentistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Cell Biology (AREA)
Immunology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2001234978A 2000-02-10 2001-02-08 Therapeutic platelets and methods Abandoned AU2001234978A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US50177300A	2000-02-10	2000-02-10
US09501773		2000-02-10
PCT/US2001/004224 WO2001058266A1 (fr)	2000-02-10	2001-02-08	Plaquettes et procedes therapeutiques

Publications (1)

Publication Number	Publication Date
AU2001234978A1 true AU2001234978A1 (en)	2001-08-20

Family

ID=23994957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001234978A Abandoned AU2001234978A1 (en)	2000-02-10	2001-02-08	Therapeutic platelets and methods

Country Status (6)

Country	Link
US (5)	US6723497B2 (fr)
EP (1)	EP1255439A4 (fr)
JP (1)	JP2004502641A (fr)
AU (1)	AU2001234978A1 (fr)
CA (1)	CA2397362A1 (fr)
WO (1)	WO2001058266A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19964109A1 (de)	1999-12-29	2001-07-05	Dade Behring Marburg Gmbh	Gebrauchsfertiges langzeitstabiles Ristocetin Cofaktor Testreagenz
US20020076445A1 (en) *	2000-02-10	2002-06-20	Crowe John H.	Eukaryotic cells and method for preserving cells
AU2001234978A1 (en) *	2000-02-10	2001-08-20	The Regents Of The University Of California	Therapeutic platelets and methods
US6653062B1 (en) *	2000-07-26	2003-11-25	Wisconsin Alumni Research Foundation	Preservation and storage medium for biological materials
US20030108972A1 (en) *	2001-12-06	2003-06-12	Zweig Stephen Eliot	Tethered receptor-ligand reagent and assay
US7294455B2 (en) *	2003-05-16	2007-11-13	The University Of North Carolina At Chapel Hill	Fixed-dried platelets cross-linked to protein
EP1677594B1 (fr) *	2003-10-09	2011-01-12	Core Dynamics Limited	Procede de congelation, de decongelation et de transplantation d'un cartilage viable
US7314755B2 (en) *	2003-10-15	2008-01-01	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Preservation of eukaryotic cells using reversible pore formation
EP1711214A1 (fr) *	2004-02-02	2006-10-18	Interface Multigrad Technology (IMT) Ltd.	Dispositif de refroidissement directionnel de matiere biologique
WO2005072523A2 (fr) *	2004-02-02	2005-08-11	I.M.T. Interface Multigrad Technology Ltd.	Materiau biologique et procedes et solutions de conservation de celui-ci
US20050191286A1 (en) *	2004-02-09	2005-09-01	Gandy James B.	Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair
CN1333126C (zh) *	2004-04-28	2007-08-22	王小建	止血纤维非织造布的制备方法
ATE460947T1 (de) *	2004-06-07	2010-04-15	Core Dynamics Ltd	Verfahren zur sterilisation von biologischen präparaten
US20060004189A1 (en) *	2004-07-02	2006-01-05	James Gandy	Compositions for treating wounds and processes for their preparation
US20060142198A1 (en) *	2004-07-02	2006-06-29	Wound Care Partners Llc	Compositions for treating wounds and processes for their preparation
US7811558B2 (en)	2004-08-12	2010-10-12	Cellphire, Inc.	Use of stabilized platelets as hemostatic agent
US8037696B2 (en) *	2004-08-12	2011-10-18	Core Dynamics Limited	Method and apparatus for freezing or thawing of a biological material
AU2005272821B2 (en) *	2004-08-12	2010-09-09	Cellphire, Inc	Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
WO2006031738A1 (fr) *	2004-09-13	2006-03-23	Hynes Richard A	Procédés pour traiter des plaies ouvertes
WO2006090372A2 (fr) *	2005-02-22	2006-08-31	I.M.T. Interface Multigrad Technology Ltd.	Cartilage viable conserve, son procede de conservation, et systeme et dispositifs de mise en oeuvre
EP1909565A2 (fr) *	2005-08-03	2008-04-16	Interface Multigrad Technology (IMT) Ltd.	Cellules somatiques utilisees dans la therapie cellulaire
WO2007027178A2 (fr) *	2005-08-30	2007-03-08	Walker Mackie J Jr	Plasma lyophilise riche en plaquettes destine a etre utilise dans la cicatrisation des plaies et dans les greffes osseuses ou tissulaires ou dans la reparation
ES2668551T3 (es)	2005-09-26	2018-05-18	Lifecell Corporation	Composición seca de plaquetas
US8277837B2 (en)	2006-01-11	2012-10-02	Entegrion, Inc.	Hemostatic textile
JP2007197353A (ja) *	2006-01-25	2007-08-09	Univ Of Tsukuba	肝再生促進剤
US8372437B2 (en)	2006-08-17	2013-02-12	Mimedx Group, Inc.	Placental tissue grafts
WO2008027917A2 (fr) *	2006-08-28	2008-03-06	The Regents Of The University Of California	Procédé pour congeler des plaquettes sanguines préservant des facteurs de croissance de plaquettes sanguines actifs
US8097403B2 (en)	2006-12-14	2012-01-17	Cellphire, Inc.	Freeze-dried platelets, method of making and method of use as a diagnostic agent
US8372427B2 (en)	2007-03-05	2013-02-12	Abbott Cardiovascular Systems Inc.	Therapeutic composition with enhanced endothelium targeting
CA2736663C (fr)	2007-09-07	2018-01-02	Surgical Biologics, Llc.	Greffons de tissu placentaire et procedes ameliores pour leur preparation et leur utilisation
US20090081785A1 (en) *	2007-09-24	2009-03-26	Hememics Biotechnologies, Inc.	Desiccated Biologics And Methods Of Preparing The Same
US20090090022A1 (en) *	2007-10-09	2009-04-09	Hememics Biotechnologies, Inc.	Desiccation Chamber and Methods for Drying Biological Materials
US8835104B2 (en) *	2007-12-20	2014-09-16	Fenwal, Inc.	Medium and methods for the storage of platelets
US20090202978A1 (en) *	2008-02-13	2009-08-13	Ginadi Shaham	Method and apparatus for freezing of a biological material
WO2010057021A1 (fr) *	2008-11-13	2010-05-20	Eastern Virginia Medical School	Activation et agrégation de plaquettes humaines et formation de gels de plaquettes par des champs électriques pulsés de l’ordre de la nanoseconde (nspef)
CN102448475A (zh) *	2009-04-09	2012-05-09	恩特格利昂公司	喷雾干燥的血液产品和制造其的方法
US8407912B2 (en)	2010-09-16	2013-04-02	Velico Medical, Inc.	Spray dried human plasma
WO2011035062A2 (fr)	2009-09-16	2011-03-24	Velico Medical, Inc.	Plasma humain séché par atomisation
EP2547760A4 (fr)	2010-02-17	2014-01-01	Hememics Biotechnologies Inc	Solutions de conservation pour des agents biologiques et procédés associés à celles-ci
EP2555613A1 (fr) *	2010-04-08	2013-02-13	INSERM - Institut National de la Santé et de la Recherche Médicale	Procédé de zéodratation utilisé pour la conservation des plaquettes sanguines
CN101957364A (zh) *	2010-09-19	2011-01-26	李勇	冻干型血小板抗原谱细胞的制备方法
US20140083628A1 (en)	2012-09-27	2014-03-27	Velico Medical, Inc.	Spray drier assembly for automated spray drying
AU2011320528A1 (en)	2010-10-29	2013-05-23	Velico Medical, Inc.	System and method for spray drying a liquid
EP2694131B1 (fr)	2011-04-07	2019-08-28	Fenwal, Inc.	Procédés et systèmes automatisés pour produire des concentrés de plaquettes avec des volumes de plasma résiduel réduits et des milieux de conservation pour de tels concentrés de plaquettes
US20150250822A1 (en) *	2012-10-04	2015-09-10	Genesys Research Institute	Platelet compositions and uses thereof
US9561184B2 (en)	2014-09-19	2017-02-07	Velico Medical, Inc.	Methods and systems for multi-stage drying of plasma
US10815456B2 (en)	2016-10-04	2020-10-27	Transwell Biotech Co., Ltd.	Composition, kit and method for cryopreserving cells
US20190076478A1 (en) *	2017-09-13	2019-03-14	Cellphire, Inc.	Canine blood platelet preparations
CA3078625C (fr)	2017-10-09	2023-01-17	Terumo Bct Biotechnologies, Llc	Recipient de lyophilisation et son procede d'utilisation
MX2020007071A (es)	2018-01-05	2020-11-11	Platelet Biogenesis Inc	Composiciones y metodos para producir megacariocitos.
WO2019224709A1 (fr) *	2018-05-22	2019-11-28	Jawaharlal Nehru University	Système d'administration d'antibiotiques
WO2020006539A1 (fr)	2018-06-29	2020-01-02	Platelet Biogenesis, Inc.	Compositions pour l'administration de médicaments et leurs méthodes d'utilisation
US11767511B2 (en)	2018-11-30	2023-09-26	Cellphire, Inc.	Platelets as delivery agents
WO2020113090A1 (fr) *	2018-11-30	2020-06-04	Cellphire, Inc.	Plaquettes utilisées comme agents d'administration
CA3224729A1 (fr)	2019-03-14	2020-09-17	Terumo Bct Biotechnologies, Llc	Ensemble et systeme de plateau de chargement pour lyophilisation
CA3138529C (fr)	2019-05-03	2025-10-07	Cellphire Inc	Materiaux et procedes de production de produits sanguins
WO2021034719A1 (fr)	2019-08-16	2021-02-25	Cellphire, Inc.	Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
CA3170134A1 (fr)	2020-02-04	2021-08-12	Cellphire, Inc.	Traitement de la maladie de willebrand
WO2021232015A1 (fr) *	2020-05-15	2021-11-18	Cellphire, Inc.	Vésicules extracellulaires dérivées de plaquettes
CN112730769A (zh) *	2021-01-29	2021-04-30	郑州普湾医疗技术有限公司	一种血小板聚集功能二磷酸腺苷杯检测试剂及其制备方法
US20220273724A1 (en)	2021-02-17	2022-09-01	Cellphire Inc.	Freeze-dried platelet derivative compositions for treating antiplatelet induced coagulopathy
WO2022225624A1 (fr) *	2021-04-20	2022-10-27	Retham Technologies, Llc	Procédés de maintien de la viabilité et de l'activité de plaquettes à long terme
US12246266B2 (en)	2022-09-15	2025-03-11	Velico Medical, Inc.	Disposable for a spray drying system
US12083447B2 (en)	2022-09-15	2024-09-10	Velico Medical, Inc.	Alignment of a disposable for a spray drying plasma system
WO2024059770A1 (fr)	2022-09-15	2024-03-21	Velico Medical, Inc.	Système de séchage par pulvérisation rapide
US11975274B2 (en)	2022-09-15	2024-05-07	Velico Medical, Inc.	Blood plasma product
US12246093B2 (en)	2022-09-15	2025-03-11	Velico Medical, Inc.	Methods for making spray dried plasma
US11841189B1 (en)	2022-09-15	2023-12-12	Velico Medical, Inc.	Disposable for a spray drying system
US11998861B2 (en)	2022-09-15	2024-06-04	Velico Medical, Inc.	Usability of a disposable for a spray drying plasma system
WO2024233577A1 (fr)	2023-05-11	2024-11-14	Vetstem, Inc.	Compositions de plasma riches en plaquettes, leur préparation et leurs utilisations

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3932943A (en)	1970-08-14	1976-01-20	E. I. Du Pont De Nemours And Company	Method of preparation of lyophilized biological products
US4145185A (en)	1977-02-25	1979-03-20	Research Triangle Institute	Reagents for screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in blood plasmas
US4287087A (en)	1977-02-25	1981-09-01	Research Triangle Institute	Fixed-dried blood platelets
US4302355A (en)	1977-08-01	1981-11-24	Warner-Lambert Company	Platelet reference control
US4251995A (en)	1979-04-25	1981-02-24	Hedbergska Stiftelsen	Method of freezing human blood platelets in glycerol-glucose using a statically controlled cooling rate device
US4548735A (en) *	1982-12-29	1985-10-22	Exxon Research And Engineering Co.	Viscosity enhancement of block polymer solutions with oil
US4717654A (en)	1984-06-19	1988-01-05	Akzo N.V.	Process for solid phase platelet antibody assay
US4585735A (en)	1984-07-19	1986-04-29	American National Red Cross	Prolonged storage of red blood cells
US5165938A (en)	1984-11-29	1992-11-24	Regents Of The University Of Minnesota	Wound healing agents derived from platelets
JPS62501631A (ja)	1985-01-11	1987-07-02	ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア	リポソ−ムの保持法
DE229810T1 (de)	1985-07-09	1987-11-05	Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire	Beschuetzung von proteinen und aehnlichem.
GB8604983D0 (en)	1986-02-28	1986-04-09	Biocompatibles Ltd	Protein preservation
US5248506A (en)	1986-03-19	1993-09-28	American National Red Cross	Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US4695460A (en)	1986-03-19	1987-09-22	American Red Cross	Synthetic, plasma-free, transfusible platelet storage medium
GB8715238D0 (en)	1987-06-29	1987-08-05	Quadrant Bioresources Ltd	Food process
US4880788A (en)	1987-10-30	1989-11-14	Baylor College Of Medicine	Method for preventing and treating thrombosis
GB8801338D0 (en)	1988-01-21	1988-02-17	Quadrant Bioresources Ltd	Preservation of viruses
US5178884A (en)	1988-05-18	1993-01-12	Cryopharm Corporation	Lyophilized and reconstituted red blood cell compositions
US5213814A (en)	1989-04-10	1993-05-25	Cryopharm Corporation	Lyophilized and reconstituted blood platelet compositions
US5045446A (en)	1988-08-26	1991-09-03	Cryopharm Corporation	Lyophilization of cells
US5958670A (en)	1988-05-18	1999-09-28	Cobe Laboratories, Inc.	Method of freezing cells and cell-like materials
US5171661A (en)	1988-05-18	1992-12-15	Cryopharm Corporation	Medium for lyophilization of erythrocytes
US5153004A (en)	1989-06-02	1992-10-06	Cryopharm Corporation	Freezing and thawing of erythrocytes
US5043261A (en)	1989-04-10	1991-08-27	Cryopharm Corporation	Lyophilized and reconstituted red blood cell and hemosome compositions
US4874690A (en)	1988-08-26	1989-10-17	Cryopharm Corporation	Lyophilization of red blood cells
US4994367A (en)	1988-10-07	1991-02-19	East Carolina University	Extended shelf life platelet preparations and process for preparing the same
US5059518A (en)	1988-10-20	1991-10-22	Coulter Corporation	Stabilized lyophilized mammalian cells and method of making same
US5030560A (en)	1988-11-04	1991-07-09	Immucor, Inc.	Method for drying mammalian cells for use in solid phase immunoassays and articles incorporating same
US5332578A (en)	1989-04-14	1994-07-26	Prp, Inc.	Platelet membrane microparticles
US5428008A (en)	1989-04-14	1995-06-27	Prp, Inc.	Therapeutic composition of micellar structures capable of promoting hemotasis
US5328840A (en)	1989-08-15	1994-07-12	The Research Foundation Of The State University Of New York	Method for preparing targeted carrier erythrocytes
US5250303A (en)	1989-10-06	1993-10-05	The American National Red Cross	Procedure for storing red cells with prolonged maintenance of cellular concentrations of ATP and 2,3 DPG
US5236716A (en)	1990-02-12	1993-08-17	Miles Inc.	Platelets concentrate with low white blood cells content
US5151360A (en)	1990-12-31	1992-09-29	Biomembrane Institute	Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US5242792A (en)	1991-02-25	1993-09-07	The United States Of America As Represented By The Secretary Of The Navy	Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides
US5376524A (en)	1991-04-01	1994-12-27	Thomas Jefferson University	Platelet storage medium containing acetate and phosphate
GB9114202D0 (en) *	1991-07-01	1991-08-21	Quadrant Holdings Cambridge	Blood products
US5344752A (en)	1991-10-30	1994-09-06	Thomas Jefferson University	Plasma-based platelet concentrate preparations
IL104470A0 (en) *	1992-01-21	1993-05-13	Cryopharm Corp	Process for freezing cells and cell like materials and compositions prepared thereby
DE69332756T2 (de) *	1992-05-29	2004-02-19	University Of North Carolina At Chapel Hill	Im immobilisierten zustand getrocknete pharmazeutische verträgliche menschliche blutplättchen
US5378601A (en)	1992-07-24	1995-01-03	Montefiore Medical Center	Method of preserving platelets with apyrase and an antioxidant
WO1994018315A1 (fr) *	1993-02-05	1994-08-18	Vascular Laboratories, Inc.	Activateurs de plasminogene intraplaquettaires du type urokinase destines a l'inhibition a long terme de la thrombose
US5358844A (en)	1993-02-18	1994-10-25	Brigham And Women's Hospital, Inc.	Preservation of blood platelets
US5510263A (en)	1993-04-05	1996-04-23	Desmos, Inc.	Growth of pancreatic islet-like cell clusters
DE69534151T2 (de) *	1994-02-22	2006-01-12	Nippon Telegraph And Telephone Corp.	Gefriergetrocknete Blutzellen, Stammzellen und Plättchen und Verfahren zu deren Herstellung
US5759542A (en)	1994-08-05	1998-06-02	New England Deaconess Hospital Corporation	Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5736313A (en)	1995-10-20	1998-04-07	The United States Of America As Represented By The Secretary Of The Navy	Method of lyophilizing platelets by incubation with high carbohydrate concentrations and supercooling prior to freezing
US5827741A (en)	1996-11-19	1998-10-27	The Regents Of The University Of California	Cryopreservation of human adult and fetal pancreatic cells and human platelets
ATE230923T1 (de)	1997-02-07	2003-02-15	Elan Drug Delivery Ltd	Verfahren und zusammensetzungen zur herstellung getrockneter, lagerungsstabiler blutplättchen
DE60002103T2 (de)	1999-11-12	2003-12-18	Elan Drug Delivery Ltd., Ruddington	Stabilisierung von blutplättchen
AU2001234978A1 (en) *	2000-02-10	2001-08-20	The Regents Of The University Of California	Therapeutic platelets and methods
US6770478B2 (en) *	2000-02-10	2004-08-03	The Regents Of The University Of California	Erythrocytic cells and method for preserving cells

2001
- 2001-02-08 AU AU2001234978A patent/AU2001234978A1/en not_active Abandoned
- 2001-02-08 EP EP01907169A patent/EP1255439A4/fr active Pending
- 2001-02-08 WO PCT/US2001/004224 patent/WO2001058266A1/fr not_active Ceased
- 2001-02-08 CA CA002397362A patent/CA2397362A1/fr not_active Abandoned
- 2001-02-08 JP JP2001557391A patent/JP2004502641A/ja not_active Withdrawn
- 2001-04-05 US US09/828,627 patent/US6723497B2/en not_active Expired - Fee Related
- 2001-08-23 US US09/938,408 patent/US20020009500A1/en not_active Abandoned
2004
- 2004-03-16 US US10/802,099 patent/US20040175374A1/en not_active Abandoned
- 2004-03-24 US US10/807,614 patent/US20040265293A1/en not_active Abandoned
2005
- 2005-12-22 US US11/317,411 patent/US20060134084A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2004502641A (ja)	2004-01-29
CA2397362A1 (fr)	2001-08-16
EP1255439A1 (fr)	2002-11-13
US20020009500A1 (en)	2002-01-24
US20010019819A1 (en)	2001-09-06
WO2001058266A1 (fr)	2001-08-16
US20040175374A1 (en)	2004-09-09
EP1255439A4 (fr)	2007-01-03
US20040265293A1 (en)	2004-12-30
US6723497B2 (en)	2004-04-20
US20060134084A1 (en)	2006-06-22

Publication	Publication Date	Title
US6723497B2 (en)	2004-04-20	Therapeutic platelets and methods
US6770478B2 (en)	2004-08-03	Erythrocytic cells and method for preserving cells
US20020076445A1 (en)	2002-06-20	Eukaryotic cells and method for preserving cells
US8802083B2 (en)	2014-08-12	Method of making platelet and poly-beta-1,4-N-acetylglucosamine fiber compositions
US8628960B2 (en)	2014-01-14	Desiccated biologics and methods of preparing the same
JPH07507443A (ja)	1995-08-24	細胞および細胞様物質を凍結する方法
US20060223050A1 (en)	2006-10-05	Therapeutic platelets and methods
US20040185524A1 (en)	2004-09-23	Biological samples and method for increasing survival of biological samples
US20040147024A1 (en)	2004-07-29	Therapeutic platelets and methods
WO2004106494A2 (fr)	2004-12-09	Agent de conservation et procede de conservation de cellules
WO2004050896A9 (fr)	2004-11-25	Plaquettes therapeutiques et methode associee
US20040136974A1 (en)	2004-07-15	Therapeutic platelets and methods
US20040152964A1 (en)	2004-08-05	Method and therapeutic platelets
WO2005002499A2 (fr)	2005-01-13	Methode et plaquettes therapeutiques
US20040191903A1 (en)	2004-09-30	Method and therapeutic platelets
AU2002330986A1 (en)	2003-02-24	Eukaryotic cells and method for preserving cells
US20050031596A1 (en)	2005-02-10	Cells and method for preserving cells
AU2002327427A1 (en)	2003-02-24	Erythrocytic cells and method for preserving cells
US20050031597A1 (en)	2005-02-10	Cells and improved method for preserving cells

Legal Events

Date	Code	Title	Description
2007-01-11	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted